Ipsen halts study on new drug formulation

France's Ipsen halted a late-stage study of a four-month formulation of triptorelin after the data didn't support sustained blood levels of the therapy. Researchers are searching for a new formulation to take the place of the three-month formulation of Decapeptyl when that patent expires. Company officials say they still expect to develop a new formulation in time.

- read the AFX report on the trial

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.